Dermatology · Flint, MI
NPI
1194740449
Since 2006
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1352 S Linden Rd
Flint, MI, 48532
Phone (810) 230-0001
Groups this clinician bills Medicare through
Medicare paid, 2024
$627K
12,684 services
Medicare patients, 2024
2,164
Average age 75
Drug cost, 2024
$5.1M
9,781 prescriptions
Company payments, 2025
$263
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kevin J Gaffney was code 17003 (destruction skin lesion), 2,947 times for 540 patients. In total Kevin J Gaffney billed 12,684 services in 100 codes, and Medicare paid $627K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-12-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 2,947 | 540 | $4.47 | $13K |
| 99213 Office E&M - Established | Office | 2,684 | 1,318 | $59.44 | $160K |
| 99214 Office E&M - Established | Office | 1,258 | 953 | $81.08 | $102K |
| 88305 Surgical Pathology Examination | Office | 1,205 | 728 | $50.54 | $61K |
| 17000 Destruction Skin Lesion | Office | 1,091 | 738 | $35.73 | $39K |
| 11102 Skin Biopsy | Office | 606 | 488 | $59.43 | $36K |
| 17110 Destruction Skin Lesion | Office | 484 | 371 | $72.46 | $35K |
| 99203 Office E&M - New | Office | 450 | 450 | $65.24 | $29K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 251 | 123 | $0.74 | $186 |
| 11103 Skin Biopsy | Office | 168 | 108 | $34.18 | $5,742 |
| 11900 Skin | Office | 147 | 103 | $36.01 | $5,294 |
| 11901 Skin | Office | 101 | 34 | $49.78 | $5,028 |
| 11301 Removal or Shaving of Skin Growth | Office | 80 | 58 | $66.92 | $5,354 |
| 17004 Destruction Skin Lesion | Office | 67 | 58 | $107.25 | $7,186 |
| 17262 Destruction Skin Lesion | Office | 61 | 55 | $116.22 | $7,090 |
By year: 2022 $667K for 13,235 services; 2023 $638K for 12,599 services; 2024 $627K for 12,684 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88305 Surgical Pathology Examination | 1,205 | 728 | $50.54 | $61K |
| 88304 Surgical Pathology Examination | 35 | 31 | $29.46 | $1,031 |
Medicare prescription drug claims, 2024
In 2024, the drug Kevin J Gaffney prescribed most often to Medicare patients was Clobetasol Propionate, with 1,185 prescriptions and refills. In total Kevin J Gaffney wrote 9,781 Medicare prescriptions that cost $5.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Clobetasol Propionate Generic | 1,185 | 1,348 | 667 | $34K |
| Mupirocin Generic | 863 | 878 | 667 | $6,018 |
| Triamcinolone Acetonide Generic | 558 | 716 | 347 | $8,232 |
| Ketoconazole Generic | 527 | 588 | 292 | $7,496 |
| Hydroxyzine Hcl Generic | 436 | 596 | 192 | $2,755 |
| Fluticasone Propionate Generic | 421 | 479 | 305 | $10K |
| Ammonium Lactate Generic | 356 | 451 | 193 | $6,067 |
| Prednisone Generic | 274 | 306 | 149 | $1,237 |
| Selenium Sulfide Generic | 272 | 319 | 118 | $3,213 |
| Doxycycline Hyclate Generic | 256 | 364 | 111 | $3,890 |
| Alclometasone Dipropionate Generic | 255 | 314 | 184 | $7,387 |
| Metronidazole Generic | 243 | 311 | 144 | $11K |
| Clindamycin Phosphate Generic | 242 | 298 | 137 | $9,038 |
| Methotrexate Methotrexate Sodium | 238 | 313 | 46 | $8,182 |
| Econazole Nitrate Generic | 217 | 271 | 131 | $5,283 |
Brand drugs: 862 claims; generic drugs: 8,919 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kevin J Gaffney $263 ($263 in general payments such as food, travel and fees) from 5 companies. The largest payer was Amgen Inc. with $143.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.